<DOC>
	<DOCNO>NCT02107404</DOCNO>
	<brief_summary>The purpose study determine whether DCVAC/PCa add radical primary prostatectomy improve PSA double time patient localized Prostate Cancer .</brief_summary>
	<brief_title>Phase II Study DCVAC/PCa Added After Radical Primary Prostatectomy Patients With Localized Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male 18 year old Histologically confirm pT2 prostate cancer Post radical prostatectomy PSA value measure value great 0.020 ng/mL result PSA double time ( PSADT ) equal less 12 month Salvage radiotherapy na√Øve PSA increase within 2 year salvage radiotherapy PSA high 1 ng/ml Eastern Cooperative Oncology Group ( ECOG ) 02 Confirmed brain and/or leptomeningeal metastases Prior androgen deprivation therapy orchiectomy prostate cancer Peripheral neuropathy Common Toxicity Criteria ( CTC ) grade 2 great Other uncontrolled intercurrent illness Treatment immunotherapy prostate cancer Clinically significant cardiovascular disease Active autoimmune disease require treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Biological</keyword>
	<keyword>Vaccine</keyword>
</DOC>